Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
ConditionVenous Thromboembolism
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorUniversity of Miami
About this trial
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
Eligibility criteria
Qualifiers
> 18 years of age
Planning to undergo a primary total hip or knee arthroplasty
Disqualifiers
History of venous thromboembolism
Active malignancy
Known pro thrombotic condition
BMI > 40
Trial design
Treatments tested in this trial
- Aspirin
Treatment groups
5,478 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov